No Data
No Data
Jefferies Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $22
Jefferies Sticks to Their Buy Rating for Terns Pharmaceuticals (TERN)
Analyst Forecasts Terns Pharmaceuticals' Upcoming CML Trial Data as Catalyst for Growth
Express News | Watching Shares Of Terns Pharmaceuticals; Traders Circulating Popular Newsletter Positively Mentioning The Company
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Announces Target Price $10
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $15